Picture

Northwestern Medicine
​Breakthroughs for Physicians

​​
  • Home
  • Specialties
    • Cardiovascular >
      • Research
      • Clinical Breakthroughs
      • News
    • Endocrinology >
      • Clinical Breakthroughs In Endocrinology
      • Research In Endocrinology
      • News
    • ENT (Otolaryngology) >
      • Clinical Breakthroughs
      • Research
      • News
    • Gastroenterology >
      • Clinical Breakthroughs
      • Research
      • News
    • Geriatrics >
      • Clinical Breakthroughs
      • Research
      • News
    • Neurosciences >
      • Rare and Complex Brain Tumors
      • Research
      • COVID-19 and Neurosciences
      • News
      • Clinical Breakthroughs
    • OB-GYN >
      • Clinical Breakthroughs
      • Research
      • News
    • Oncology >
      • Clinical Breakthroughs
      • Research
      • News
    • Ophthalmology >
      • Clinical Breakthroughs
      • Research
      • News
    • Organ Transplant >
      • Clinical Breakthroughs
      • Research
      • News
    • Orthopaedics >
      • Clinical Breakthroughs
      • Research
      • News
    • Psychiatry >
      • Clinical Breakthroughs
      • Research
      • News
    • Pulmonary >
      • Clinical Breakthroughs
      • Research
      • News
    • Rehabilitation >
      • Clinical Breakthroughs
      • News
    • Rheumatology >
      • Clinical Breakthroughs
      • Research
      • News
    • Urology >
      • Clinical Breakthroughs
      • Research
      • News
  • CME
  • REFERRALS
    • Refer to NM Cardiovascular
    • Refer to NM Neurosciences
    • Refer to Other Specialties

< BACK TO CLINICAL BREAKTHROUGHS IN PULMONARY

March 2022

PULMONARY

FIRST POTENTIAL IMMUNIZATION AGAINST RSV FOR HEALTHY INFANTS FOUND HIGHLY EFFECTIVE IN PHASE 3 TRIAL

Featuring: William J. Muller, MD, PhD

​Single dose of nirsevimab protected infants across the entire RSV season

​The new drug nirsevimab showed 74.5 percent efficacy against medically attended lower respiratory tract infections caused by respiratory syncytial virus (RSV) in healthy infants, according to an international, randomized, placebo-controlled phase 3 clinical trial published in the New England Journal of Medicine.

It is the first potential immunization against RSV in the general infant population, with a single dose providing safe protection across the entire RSV season.

“These exciting data show that nirsevimab has the potential to offer RSV protection for all infants, which would be a paradigm shift in the approach to this disease,” said site principal investigator and co-author William J. Muller, MD, PhD, scientific director of clinical and community trials at Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago, and an associate professor of Pediatrics in the Division of Infectious Diseases.

RSV is a common, contagious virus that causes seasonal epidemics of lower respiratory tract infections, leading to bronchiolitis and pneumonia in infants. It is also a leading cause of hospitalizations in all infants.

The trial involved healthy term and late preterm (gestational age 35 weeks or older) infants entering their first RSV season. Lurie Children’s was among the highest enrolling US sites in the trial.

Nirsevimab is an investigational long-acting monoclonal antibody developed by AstraZeneca and Sanofi, designed to protect all infants through their first RSV season with a single dose. Monoclonal antibodies do not require the activation of the immune system to help offer rapid and direct protection against disease.

Currently, the only available preventative option for RSV is palivizumab, which is limited to high-risk infants and provides one-month protection, requiring five injections to cover an RSV season.

A separate Phase 2/3 trial, also published in the New England Journal of Medicine, evaluated the safety of nirsevimab in infants with congenital heart disease, chronic lung disease and prematurity entering their first RSV season. The trial demonstrated that nirsevimab had a similar safety and tolerability profile compared to palivizumab. Results in this population of infants indicated similar protection against RSV to that of healthy term and late preterm infants.
​
“We know that RSV has seen a resurgence with the easing of COVID-19 public health measures. This shows us a broad immunization approach is needed to help mitigate the substantial global burden RSV places on infants, their families and healthcare services,” Muller said.

Listen to an episode of the Breakthroughs Podcast with William J. Muller, MD, PhD

​
​This article was originally published in the Northwestern University Feinberg School of Medicine News Center on March 9, 2022. ​
YouYang Zhao, PHD photo
William J. Muller, MD, PhD, the scientific director of clinical and community trials at Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago, and an associate professor of Pediatrics in the Division of Infectious Diseases.

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​
Call 844.344.6663
Find an NM PULMONOLOGIST

You May Also Like

David Odell, MD Headshot

November 2021

PULMONARY
Northwestern Medicine Launches the Canning Thoracic Institute to Meet the Growing Patient Demand for Lung Care
Samuel Kim, MD in Surgical Scrubs

February 2022

PULMONARY
Lung Transplant Safe for COVID-19 Patients, Northwestern Medicine Finds
physicians wearing masks

November 2022

PULMONARY
Northwestern Medicine Performs First Successful Lung-liver Transplant

Northwestern Medicine Breakthroughs for Physicians

About Us     Terms of Use     Privacy Policy     How to Vote for U.S. News & World Report Best Hospitals
© 2025 Northwestern Medicine® and Northwestern Memorial HealthCare. 
Northwestern Medicine® is a trademark of Northwestern Memorial HealthCare, used by Northwestern University
Connect with us
[email protected]
International physicians, contact [email protected]
  • Home
  • Specialties
    • Cardiovascular >
      • Research
      • Clinical Breakthroughs
      • News
    • Endocrinology >
      • Clinical Breakthroughs In Endocrinology
      • Research In Endocrinology
      • News
    • ENT (Otolaryngology) >
      • Clinical Breakthroughs
      • Research
      • News
    • Gastroenterology >
      • Clinical Breakthroughs
      • Research
      • News
    • Geriatrics >
      • Clinical Breakthroughs
      • Research
      • News
    • Neurosciences >
      • Rare and Complex Brain Tumors
      • Research
      • COVID-19 and Neurosciences
      • News
      • Clinical Breakthroughs
    • OB-GYN >
      • Clinical Breakthroughs
      • Research
      • News
    • Oncology >
      • Clinical Breakthroughs
      • Research
      • News
    • Ophthalmology >
      • Clinical Breakthroughs
      • Research
      • News
    • Organ Transplant >
      • Clinical Breakthroughs
      • Research
      • News
    • Orthopaedics >
      • Clinical Breakthroughs
      • Research
      • News
    • Psychiatry >
      • Clinical Breakthroughs
      • Research
      • News
    • Pulmonary >
      • Clinical Breakthroughs
      • Research
      • News
    • Rehabilitation >
      • Clinical Breakthroughs
      • News
    • Rheumatology >
      • Clinical Breakthroughs
      • Research
      • News
    • Urology >
      • Clinical Breakthroughs
      • Research
      • News
  • CME
  • REFERRALS
    • Refer to NM Cardiovascular
    • Refer to NM Neurosciences
    • Refer to Other Specialties